CD274 and neoplasm: Immune checkpoint blockade (ICB) drugs targeting programmed cell death 1 (PD1), programmed cell death ligand 1 (PD‐L1), and cytotoxic T lymphocyte antigen 4 (CTLA4) are currently being tested for the treatment of recurrent/metastatic cervical cancers.[15, 16, 17] Unfortunately, the overall response rates to ICB therapy are low, varying from 4% to 26%.[15, 18, 19, 20] Clarifying the immune landscape of CSCC, especially the immunosuppression status in the tumor microenvironment (TME), may help us better address this phenomenon and adjust our treatment strategy for cervical cancers.